Pfizer Inc. today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in ...
Key points A 39-year-old woman with a known history of antiphospholipid syndrome (APS) presented to the emergency department with acute shortness of breath, pleuritic chest pain, and presyncope. On ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results